Generalized anxiety disorder (GAD) is a chronic anxiety condition characterized by excessive, difficult-to-control worry about everyday events for at least six months. It often co-occurs with depression and other anxiety disorders.
Common symptoms include restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance. GAD is typically treated first with SSRIs, SNRIs, or cognitive behavioral therapy. When standard treatments are not sufficient, ketamine therapy is increasingly studied as an option for treatment-resistant anxiety.
NeuroGlow offers IV ketamine therapy for patients with treatment-resistant generalized anxiety disorder, panic disorder, or social anxiety, used off-label based on growing clinical evidence.
Generalized Anxiety Disorder (GAD) is characterized by excessive worry that persists for at least six months and interferes with daily functioning. GAD is commonly comorbid with major depressive disorder, and patients with both conditions often respond well to IV ketamine therapy, which addresses anxiety symptoms through the same NMDA-receptor mechanism that treats depression. The GAD-7 screening tool is used to track severity. See our anxiety treatment page for clinical detail on how we treat GAD with IV ketamine.